1271 Stock Overview
Focuses on professional research and development, and technical material manufacturing and processing business. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
SunWay Biotech Co., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$85.00 |
| 52 Week High | NT$145.50 |
| 52 Week Low | NT$81.00 |
| Beta | -0.15 |
| 11 Month Change | -8.41% |
| 3 Month Change | -0.47% |
| 1 Year Change | -0.58% |
| 33 Year Change | 35.57% |
| 5 Year Change | n/a |
| Change since IPO | 20.91% |
Recent News & Updates
Shareholder Returns
| 1271 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -4.5% | 1.4% | 0.8% |
| 1Y | -0.6% | 7.5% | 30.3% |
Return vs Industry: 1271 underperformed the TW Pharmaceuticals industry which returned 7.5% over the past year.
Return vs Market: 1271 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 1271 volatility | |
|---|---|
| 1271 Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1271 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1271's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | n/a | sunway.cc |
SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business. The company researches, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus paracasei subsp.
SunWay Biotech Co., LTD. Fundamentals Summary
| 1271 fundamental statistics | |
|---|---|
| Market cap | NT$5.05b |
| Earnings (TTM) | NT$99.60m |
| Revenue (TTM) | NT$810.99m |
50.7x
P/E Ratio6.2x
P/S RatioIs 1271 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1271 income statement (TTM) | |
|---|---|
| Revenue | NT$810.99m |
| Cost of Revenue | NT$387.74m |
| Gross Profit | NT$423.25m |
| Other Expenses | NT$323.65m |
| Earnings | NT$99.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.68 |
| Gross Margin | 52.19% |
| Net Profit Margin | 12.28% |
| Debt/Equity Ratio | 0.3% |
How did 1271 perform over the long term?
See historical performance and comparison